Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment by Slade, M J et al.
Comparison of bone marrow, disseminated tumour cells and
blood-circulating tumour cells in breast cancer patients after
primary treatment
MJ Slade
1, R Payne
1, S Riethdorf
2, B Ward
3, SAA Zaidi
1, J Stebbing
1, C Palmieri
1, HD Sinnett
3,
E Kulinskaya
4, T Pitfield
5, RT McCormack
6, K Pantel
2 and RC Coombes*,1
1Department of Oncology, Imperial College, MRC Cyclotron Building, London W12 0NN, UK;
2Institute of Tumor Biology, University Medical Center
Hamburg-Eppendorf, Hamburg D-20246, Germany;
3Department of Medical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital,
Fulham Palace Road, London W6 8RP, UK;
4Statistical Advisory Service, Imperial College, South Kensington Campus, London SW7 1NA, UK;
5Veridex
LLC, 50-100 Holmers Farm Way, High Wycombe, HP12 4DP, UK;
6Veridex LLC, 33 Technology Drive, Warren, NJ 07059, USA
The purpose of this study was to determine whether primary breast cancer patients showed evidence of circulating tumour cells
(CTCs) during follow-up as an alternative to monitoring disseminated bone marrow tumour cells (DTCs) by immunocytochemistry
and reverse transcriptase (RT)–PCR for the detection of micrometastases. We planned to compare CTC and DTC frequency in
low-risk and high-risk patients. We identified two cohorts of primary breast cancer patients who were at low (group II, T1N0, n¼18)
or high (group III, 43 nodes positive (with one exception, a patient with two positive nodes) n¼33) risk of relapse who were being
followed up after primary treatment. We tested each cohort for CTCs using the CellSearch system on 1–7 occasions and for DTCs
by immunocytochemistry and RT–PCR on 1–2 occasions over a period of 2 years. We also examined patients with confirmed
metastatic disease (group IV, n¼12) and 21 control healthy volunteers for CTCs (group I). All group I samples were negative for
CTCs. In contrast, 7 out of 18 (39%) group II primary patients and 23 out of 33 (70%) group III patients were positive for CTCs
(P¼0.042). If we count only samples with 41 cell as positive: 2 out of 18 (11%) group II patients were positive compared with 10
out of 33 (30%) in group III (P¼0.174). In the case of DTCs, 1 out of 13 (8%) group II patients were positive compared with 19 out
of 27 (70%) in group III (Po0.001). Only 10 out of 33 (30%) patients in group III showed no evidence of CTCs in all tests over the
period of testing, compared with 11 out of 18 (61%) in group II (P¼0.033). A significant proportion of poor prognosis primary breast
cancer patients (group III) have evidence of CTCs on follow-up. Many also have evidence of DTCs, which are more often found in
patients who were lymph node positive. As repeat sampling of peripheral blood is more acceptable to patients, the measurement of
CTCs warrants further investigation because it enables blood samples to be taken more frequently, thus possibly enabling clinicians to
have prior warning of impending overt metastatic disease.
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Breast cancer is the most common cancer among women in the
United States and Europe. Although mammographic screening and
the judicious use of adjuvant systemic therapy have improved the
survival from this disease, many patients still relapse and develop
metastatic disease. Metastases inevitably result in the death of the
patient.
Over the past 10 years, long-term follow-up of patients in trials
designed to evaluate adjuvant endocrine or cytotoxic chemother-
apy has indicated that cure can be achieved in a proportion of
patients by these treatments. For this reason, considerable efforts
have been made to discover a means of monitoring these patients,
in the hope of finding a test that would distinguish those who need
further sequential adjuvant therapy from those for whom this
treatment would not be necessary. This has become particularly
important on account of our recent studies showing that ‘interval’
or ‘switching’ techniques improve disease-free (Coombes et al,
2004) and overall survival (Coombes et al, 2007).
Several studies have now shown that the presence of occult
metastases in the bone marrow identifies a population of patients
at high risk for recurrence (Redding et al, 1983; Cote et al, 1988;
Diel et al, 1996; Mansi et al, 1999; Braun et al, 2000c; Wiedswang
et al, 2003; Naume et al, 2004). In our original study (Neville et al,
1983), the presence of bone marrow occult metastases was
correlated with tumour stage and vascular invasion, both of which
are known predictors of poor prognosis. Other studies of note are
Diel et al (1996) and Braun et al (2000b) who analysed bone
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smarrows from 727 and 552 patients, respectively, using immuno-
cytochemistry (ICC). Both these studies have shown that the occult
bone marrow metastases were associated with larger tumour size,
lymph mode involvement and high-grade tumour. The presence of
micrometastases in bone marrow at surgery has been shown to be
an independent prognostic factor in 817 breast cancer patients
(Wiedswang et al, 2003). In a pooled analysis of 4703 patients with
stages I, II or III breast cancer with 10-year follow-up (Braun et al,
2005), micrometastases at diagnosis were detected in 30.6% of
patients. Those patients with micrometastases had larger tumours
and higher histological grade and more frequent lymph node
metastases and hormone receptor-negative tumours. This study
shows that the presence of micrometastases in the bone marrow at
the time of diagnosis of breast cancer was an independent
predictor of a poor outcome and is associated with poor prognosis.
In studies from our laboratory and from others, it has been
shown that it is possible to detect residual disseminated bone
marrow tumour cells (DTCs) in the bone marrow, and circulating
tumour cells (CTCs) in the peripheral blood during follow-up.
However, the number of cells in the bone marrow is small even
after using the best available techniques (i.e., using a pancyto-
keratin antibody (A45-B/B3), which is well characterized for DTC
studies (Braun et al, 2000b)) for staining 2 10
6 cells and
analysing automatically. On account of the difficulties inherent
in subjecting patients to regular bone marrows, as well as the small
number of cells detected in primary patients with no evidence of
overt metastases, such tests have been difficult to apply in routine
clinical practice. Furthermore, until recently, the peripheral blood
has been shown to be generally negative for CTCs in all but a
minority of patients, with most series showing 1–5% of patients
found to be positive (Schoenfeld et al, 1997; Slade et al, 2005).
Many groups have attempted to develop a reproducible
methodology for CTC detection to improve the detection rate.
One of these is the CellSearcht (Veridex LLC, Warren, NJ, USA)
system with which Cristofanilli et al (2004) carried out a study of
177 patients with metastatic breast cancer. The results from this
approach indicated that approximately 70% of patients with
metastatic breast cancer have 41 CTC/7.5ml of peripheral blood.
They also found that patients with five or more CTCs per 7.5ml of
blood had a significantly worse progression-free and overall
survival than patients with o5 cells per 7.5ml of blood
(progression-free survival was 2.1 vs 7.0 months and overall
survival was 8.2 vs 18 months). It has subsequently been shown
(Hayes et al, 2006) in this group of patients that elevated CTCs at
any time during therapy are an accurate indicator of rapid disease
progression and mortality.
We therefore decided to perform a pilot study to determine
whether monitoring for CTCs using the CellSearch system was
comparable with our current micrometastatic monitoring system
using ICC and reverse transcriptase (RT)–PCR of bone marrow
samples. This was performed in a group of patients on follow-up
after a diagnosis of breast cancer, and none of them had evidence
of overt metastases.
MATERIALS AND METHODS
Patients
The study was approved by each local ethics committee and
conducted in accordance with the declaration of Helsinki and all
patients gave written informed consent. Samples were blinded for
analysis and patients understood that the results would not be
made available to them. Patients diagnosed with early stage breast
cancer, who were on routine follow-up, were invited to take part in
the study. All women were attending local hospitals in the West
London Cancer Network. All patients had previously histologically
confirmed primary breast cancer and no evidence of distant
metastases on chest radiology, bone scanning or liver ultrasound.
It was not possible to compare the two sampling sites (i.e., blood
and bone marrow), as the samples were not taken at identical time
points for ethical reasons.
Breast cancer patients
To have a group of patients who were at very low risk of having
recurrence in the future, we decided to take the subset of patients
from our published study (Slade et al, 2005) to include only those
patients with T1N0 (i.e., those who had a tumour p2cm)and who
were node negative (group II) 4–13 years post-surgery. For the
high-risk group (group III), we included patients who previously
had 43 node-positive breast cancer (with one exception, a patient
with two positive nodes) and were on follow-up and who had no
sign or symptom of recurrence. We examined 3 7.5ml samples
of blood from all of these patients together with the same amount
of blood from a cohort of women with no past history of breast
cancer (negative control – group I). We repeated the sampling
procedure 1–7 times over a 2-year period. As positive controls, we
took 1 7.5ml blood from a group of 12 patients with overt
metastatic breast cancer (group IV).
Preparation of bone marrow samples
The skin was incised before the aspirates were taken to minimise
the risk of epithelial contamination. Between 2 and 5ml of bone
marrow was aspirated into syringes primed with preservative-free
heparin (Leo Labs, Risborough, UK). Bone marrow samples were
prepared as described earlier (Slade et al, 1999; Smith et al, 2000).
Ficoll (GE Healthcare, Chalfont St Giles, UK) was used to separate
the mononucleocytes; these were counted and aliquoted for ICC on
the basis of ideally 6 10
6 cells for each methodology but with a
minimum of 3 10
6 cells for each. Those undertaking the ICC
were blind to the clinical status and identity of the patients and
their earlier assay results.
Immunocytochemistry
Cells were cytocentrifuged at a concentration of 5 10
5 per
cytospin, air dried and stained as described earlier (Pantel et al,
1994; Slade et al, 1999; Smith et al, 2000). A total of six areas were
stained, of which four were stained for the presence of cytokeratin-
positive cells and two were isotype controls. The primary antibody
(A45-B/B3 Micromet, Munich, Germany) directed to a common
epitope of cytokeratin (Stigbrand et al, 1998) was used at
2mgml
 1. The rabbit anti-mouse antiserum (Z259; Dako,
Hamburg, Germany) and the alkaline phosphatase anti-alkaline
phosphatase (APAAP) complex (D651; Dako) were used as
recommended by the manufacturer and the reaction developed
with new fuchsin. An isotype IgG1 mouse myeloma antibody
MOPC-21 (Sigma Aldrich, Poole, UK) served as negative control
and the MCF-7 cell line as a positive control (Pantel et al, 1994;
Slade et al, 1999; Smith et al, 2000). The cytospins were
counterstained with haematoxylin and screened using the Auto-
mated Cellular Imaging System (ACIS) (Carl Zeiss Ltd, Welwyn
Garden City, UK). Samples that were isotype positive were deemed
uninterpretable and therefore excluded from the results.
CellSearch
Blood, 7.5ml from the metastatic patients and 3 7.5ml from the
control and primary breast cancer patients, was collected in
CellSavet preservative tubes (Immunicon, Huntingdon, PA, USA)
from patients in London, anonymised, and transported at room
temperature to either the Institute of Tumor Biology in Hamburg
or the Department of Oncology, Imperial College London for
processing within 72h of collection as recommended by the
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smanufacturer. The CellSearch system was used for the isolation
and enumeration of CTCs from each 7.5ml of blood separately.
The CellSearch Epithelial Cell Kit (Veridex) enriches the sample
for cells expressing the epithelial-cell adhesion molecule (Ep-CAM)
with antibody-coated magnetic beads, and labels the cells with the
fluorescent nucleic acid dye 4,2-diamidino-2-phenylindole dihy-
drochloride (DAPI). Fluorescently-labelled monoclonal antibodies
raised against leukocytes (CD45-allophycocyanin) and epithelial
cells (cytokeratin 8, 18, 19-phycoerythrin) are used to distinguish
epithelial cells from leukocytes. The identification and enumera-
tion of CTCs were performed with the use of the CellTracks
Analyzer (Immunicon), a semi-automated fluorescence-based
microscopy system that permits computer-generated reconstruc-
tion of cellular images. Circulating tumour cells were defined as
nucleated cells lacking CD45 and expressing cytokeratin in
accordance with the criteria specified by Veridex.
Real-time QPCR
Real-time QPCR for CK-19 and ABL was performed using the
LightCyclert (Roche Diagnostics, Mahnheim, Germany). The
assay used the LightCycler DNA FastStart SYBR Green 1 kit
(Roche Diagnostics) using 2ml of combined dNTPs, Taq DNA
polymerase and SYBR Green plus 2.5ml of cDNA and 0.625mM of
primers in a total volume of 20ml.
Primers
CK-19S 50-GCGGGCAACGAGAAGCTAA-30
CK-19Do 50-CTCATGCGCAGAGCCTGTT-30
A2N 50-CCCAACCTTTTCGTTGCACTGT-30
A4- 50-CGGCTCTCGGAGGAGACGTAGA-30
The standard used for quantitation was the artificial construct
described earlier (Slade et al, 1999), in the range 10
1–10
4 for CK-19
and 10
3–10
6 for ABL per 2.5ml.
Statistical methods
Owing to the small numbers, exact two-sided non-parametric tests
were used throughout at 5% level of significance. The exact
Pearson w
2-test was used for testing association of two categorical
variables, the Mann–Whitney test for the comparison of
continuous variables between the two groups, and the Spearman
correlation for correlations of two continuous variables.
RESULTS
To perform this pilot study, we recruited 51 primary breast cancer
patients (18 group II T1N0 ‘low risk’ and 33 group III 43 nodes
positive (with one exception, a patient with two positive nodes)
‘high risk’ patients) who were on routine follow-up, with no
clinical evidence of disease, 4–13 years after diagnosis. No patient
had any sign or symptom of metastatic breast cancer. Two control
populations were also recruited, 21 non-cancer controls (group I)
and 12 metastatic patients (group IV), to confirm earlier results
with the CellSearch system (Cristofanilli et al, 2004, 2005;
Riethdorf et al, 2007). Overall, 14 patients in group III and one
patient in group II were taking adjuvant endocrine therapy. No
patient changed treatment during the course of the monitoring
period. Patients in group II had one bone marrow sample taken
yearly. The higher risk patients in group III had two bone marrows
taken 6–12 months apart. All patients had between 1–7 samples of
peripheral blood taken (three tubes or 22.5ml of blood at each
time point) for immunocytochemical evaluation using the
CellSearch system approximately 6–34 months apart. These
patients also had an isotopic bone scan, liver ultrasonography and
chest radiology, as well as blood evaluation for full haematological
and biochemical screen to exclude overt metastatic disease. All but
two patients had no evidence of metastatic disease. For ethical
reasons, the non-cancer controls had two blood tests (15ml) for the
CellSearch system and only patient groups II and III had bone
marrow aspirates taken. The number of CTCs and DTCs present in
blood and bone marrow, respectively, were compared in the low- and
high-risk primary breast cancer patient groups.
CTC results
In the patients with overt metastases, we found CTCs in seven
patients; the mean number of cells detected was 51 with a range
of 0–301. Fewer patients (7 out of 18 (39%)) in group II
compared with group III (23 out of 33 (70%)) had at least one
CTC (P¼0.042, exact w
2-test). Results are shown for all patients in
Tables 1 and 2. We then analysed our results taking 41 cell as
positive: 2 out of 18 (11%) patients in group II vs 10 out of 33
(30%) in group III were positive using this cutoff point (P¼0.174,
exact w
2-test).
Groups II and III patients were tested for CTCs using the
CellSearch system at 1–7 time points. There was no difference in
the number of tests between the groups (P¼0.812), although the
time from diagnosis to the start of testing and the time of intervals
between tests were not associated with the results of the CTC tests
within the groups (P-values 0.274 and 0.602). Neither oestrogen
receptor (ER) or progesterone receptor (PR) status nor tumour
size affected the proportion of the CTC-positive tests within each
group (P¼0.374 and P¼0.238).
None of the non-cancer controls had any evidence of CTCs. Of
the 18 group II patients five (28%) were positive at one time point,
and two (11%) at two time points. By contrast, in group III, 13
(39%) patients were positive at one time point, six (18%) at two
time points and four (12%) at three time points.
In all, only 10 out of 33 (30%) patients in group III showed no
evidence of CTCs in all tests over the period of testing, compared
with 11 out of 18 (61%) in group II (P¼0.033). The negative
patients may reflect the potentially small number of patients who
will not clinically relapse. Two patients developed evidence of
overt metastases during the course of the study. Both of these
patients had positive results on the CellSearch system, and in each
patient, DTCs were detected by ICC in one of the two bone
marrows and by QPCR in two of the bone marrows.
The chances of finding positive results did not seem affected by
whether or not the patients were receiving endocrine therapy at the
time of sampling (P¼0.389 and P¼0.693 for groups II and III,
respectively).
Over this period of sampling for CTCs, we obtained 68 bone
marrow samples for DTC analysis; 13 patients in group II and one
patient in group III were tested once, and 27 patients in group III
at two time points. Overall, 1 out of 13 patients (8%) in group II
were positive for DTCs in contrast to the 19 out of 27 positive at
least once when tested at two time points in group III (Po0.001).
Only 8 out of 27 (30%) patients in group III were negative at
both time points, 16 out of 27 were positive once, and 3 out of 27
positive at two time points, but none had two or more cells at both
time points (see Tables 1 and 2).
For bone marrow QPCR, none of the 13 patients in group II
were positive in contrast to 16 of 27 patients tested at two
time points in group III (Po0.001); 16 were positive at both time
points.
We also studied the relationship between the DTC results and
the CTC results. Patients consistently negative for DTCs in bone
marrow (measured by ICC) can have positive CTCs (5 out of 12 in
group II and 4 out of 8 in group III), but among the patients with
positive DTCs, there is a high proportion of patients with positive
CTCs (16 out of 19 (84%) in group III). These numbers were too
small to reach statistical significance (P¼0.145).
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sDISCUSSION
These data indicate that some patients who have had a diagnosis of
breast cancer have evidence of micrometastatic breast cancer during
follow-up, despite having no clinical evidence of metastases. Seven
of 18 (39%) of the T1N0, group II patients were found to have CTCs
compared with 23 of 33 (70%) of the patients with lymph-node-
positive disease. Although the numbers of patients in this pilot study
are small, the results suggest that the likelihood of finding CTCs and
DTCs on follow-up is greater in the patients who are at higher risk
of recurrence (P¼0.042 and Po0.001, respectively) and that the
numbers of CTCs are greater in the poor-risk patients.
We have previously published the fact that there is occasional
evidence of DTCs on follow-up of patients over 4 years after
treatment for primary breast cancer (Slade et al, 2005). Most
patients show considerable variability. In this pilot study, we have
intensively investigated a cohort of patients and found, on
the basis of one or two separate tests over a 2-year follow-up
period, that many patients show positive tests, sometimes con-
firmed by the CellSearch test for CTCs. It may be significant that a
proportion of patients with bad prognosis on the basis of their
tumour histology showed consistently negative results. None of
these relapsed with overt disease during the course of the study,
compared with two patients in the group with positive results.
There have been few studies in primary breast cancer patients,
either at presentation or at follow-up. Wulfing et al (2006) discovered
that 50% of patients had evidence of HER-2-positive cells in the
blood and that this correlated with survival. It can be noted that
some patients who were initially judged to have HER-2-negative
tumours had HER-2-positive CTCs. It can be noted that some
patients who were initially judged to have HER-2 negative tumours
had HER-2 positive CTCs. A study of 456 primary patients showed
that 28% had X1C T Ci n3  7.5ml of blood but the presence of
CTCs did not correlate with any prognostic features of the primary
tumour (Rack et al, 2006). Studies such as this are necessary in order
to determine a cut-off for positivity in primary patients (both this
study and ours used a cut-off of a single CTC) with clinical follow-up
and also studies in patients with benign breast disease.
Discrepancies between the findings for DTCs and CTCs may be
explained either by differences in the methodology of detection
(RT–PCR for CK-19 only, as compared with ICC for CK8, 18 and
19 for the DTCs and Ep-CAM enrichment, followed by pan-
cytokeratin staining for CTCs), or because DTCs and CTCs
represent two different levels of risk. It has been shown that CTCs
have a half-life of 1–2.4h (Meng et al, 2004) and are non-
replicating (Muller et al, 2005) and that these must be replenished
by replicating cells from elsewhere. Potentially, this could be the
bone marrow; however, the DTCs, when in the bone marrow, are
also non-replicating in the majority of primary breast cancer
patients (Pantel et al, 1993; Muller et al, 2005). In each case, we
have used the best available methodologies for detecting the cells
and further studies on a larger cohort of patients along with
improvements in assays, for example, CellSearch applied to bone
marrow aspirates, may improve the correlation between CTCs and
DTCs. With regard to the CTCs and DTCs being biologically and
genetically different cells or DTCs in bone marrow being a subset
of CTCs circulating in blood, we are currently investigating this
using single-cell PCR and microarray analysis.
The most commonly used methods for detection of tumour cells
in breast cancer are immunocytochemistry and molecular methods
in the form of RT–PCR. There has been extensive research into
methods for detection of occult micrometastases in patients before
clinical manifestation. To date, bone marrow has been the most
common site investigated for micrometastatic organ involvement.
This is probably because of easy accessibility and the physio-
logical absence of epithelial cells in the bone marrow, and
also because the bone marrow is a homing site and blood is a
transition compartment, two different biological compartments
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sTable 2 Patient characteristics, details of therapy and timing of bone marrow and peripheral blood sampling in group III patients
Patient
no.
Date
of
diagnosis
Tumour
type
Size
(mm) Grade
No.
of
LN
ER
status
PR
status
Therapy
during
study
Time
from
diagnosis
BM1
(months) QPCR ICC
Time
from
diagnosis
BM2
(months) QPCR ICC
Time
from
diagnosis
PB1
(months) CTCs
Time
from
diagnosis
PB2
(months) CTCs
Time
from
diagnosis
PB3
(months) CTCs
Time
from
diagnosis
PB4
(months) CTCs
Time
from
diagnosis
PB5
(months) CTCs
Time
from
diagnosis
PB6
(months) CTCs
Time
from
diagnosis
PB7
(months) CTCs
19 09/01/1999 IDC 30 3 4\13 3+ — Arim 78 0.12 0 84 0.25 2 77 2 ND 99 0 ND 105 0 108 0 111 1
20 09/01/1995 IDC 30 3 12\17 1+ 1+ Nil 126 0.18 1 132 0.11 1 125 0 132 0 149 0 152 1 156 2 159 0
21 07/01/1994 ILC 450 3 12\16 — — Nil 137 0.10 0 143 0.47 7 135 5 140 0 162 0 165 0 167 1 170 0
22 05/01/1997 IDC 27 3 6\19 Neg Neg Nil 102 0.22 3 108 0.08 0 102 1 108 0 125 1 128 1 ND 134 0
23 01/01/1996 IDC 33 3 4\20 — — Nil 117 0.03 0 123 0.00 0 119 0 125 0 138 0 141 1 144 0 147 0
24 09/01/1996 ILC 55 2 5\29 3+ 2+ Nil 129 0.02 1 135 0.10 1 119 0 124 0 138 0 142 0 ND 148 0
25 23/12/1997 Tubular 11 - 2\13 Pos Pos Tam 113 0 117 0 121 0 123 0
26 12/03/1997 IDC 16 2 16\36 1+ 1+ Arim 92 0.14 0 104 0.00 0 98 0 100 0 122 0 126 0 129 0 132 0
27 08/01/1999 IDC 10 2 5\15 3+ 3+ Arim 68 0.22 1 74 0.04 0 76 0 82 0 100 0 104 0 107 0 112 0
28 01/01/1997 IDC 20 3 8\21 Neg Neg Nil 107 0.20 3 113 0.20 0 106 0 112 2 Relapsed with metastatic disease 115 months after diagnosis
29 11/01/1998 IDC 30 3 6\18 Neg Neg Nil 78 0.12 1 84 0.20 1 84 0 90 0
30 02/01/2000 IDC 13 3 9\21 Pos Neg Arim 70 0.18 1 76 0.32 0 ND 76 0 89 0 92 0 94 1 97 0 100 0
31 05/01/1998 IDC 25 3 6\11 Pos — Nil 91 0.03 6 97 0.09 0 91 0 ND 113 0 116 0 119 0 121 0 124 1
32 03/01/1997 IDC 60 3 4\31 Neg Neg Nil 104 0.03 0 110 0.52 1 104 0 110 0 125 1 128 0 131 0 133 0
33 27/09/1994 IDC 23 3 9\29 — — Nil 151 0 154 2 157 0 161 0 164 0
34 03/01/1995 Both IDC 2 16
and 22
3 9\24 1+ 1+ Nil 126 0.06 0 132 0.13 3 132 8 136 0
35 05/01/1997 IDC 50 3 4\22 Neg Neg Nil 95 0.02 0 101 0.00 0 95 0 101 0 125 0 ND ND 132 0
36 09/01/1997 T2 N1 25 2 11\20 2+ 2+ Nil 90 0.06 0 96 0.06 1 96 0 109 0 124 0 127 0 130 1 133 1 136 0
37 10/01/1995 ILC 35 2 9\21 — — Nil 122 0.01 0 128 0.07 0 123 0 127 0 149 0 152 0 ND
38 06/01/1999 IDC plus
DCIS
25 3 4\29 2+ 2+ Arim 78 0.01 0 84 0.05 0 78 0 84 0 100 1 103 1 107 23 112 0
39 09/01/1997 IDC 40 3 10\21 1+ 1+ Nil 93 0.02 1 99 0.00 0 99 0 103 0 126 1 ND 130 0 133 0
40 02/01/1999 IDC 45 3 6\14 Pos Pos Arim 84 0 0 90 0.13 0 84 0 90 0 105 0 108 1 111 0
41 03/01/1998 IDC 40 2 7\27 Pos Pos Arim 94 0.07 0 100 0.07 0 93 0 100 0 115 0 118 0 120 0
42 08/12/1997 Multifocal
IDC
450 2 9\20 2+ 3+ Arim 112 0 115 1 119 0 122 1 125 2
43 09/01/1997 TX N4 — 3 14\25 Neg Neg Nil 95 0.04 1 101 0.03 0 101 1 105 0
44 04/01/1998 IDC 60 2 8\19 — — Tam 74 0.11 0 86 0.23 1 ND 96 7 Relapsed with metastatic disease 101 months after diagnosis
45 05/09/1995 IDC 18 2 8\13 2+ Neg Nil 144 0 147 0 151 0
46 08/01/1997 IDC 20 2 7\19 3+ 3+ Nil 85 0.12 1 97 0.26 0 101 0 106 0 126 0 129 1 132 0 135 0
47 29/12/2003 IDC 15 3 45\45 Neg Neg CT (FEC) 41 0 44 0 ND 49 0 53 0
48 16/12/1998 Mucoid
carcinoma
50 1 8\19 2+ 3+ Arim 72 0.03 0 84 0.05 0 84 3 97 0 103 0 106 0 109 1 112 0
49 08/01/1999 IDC 20 3 4\26 Neg Neg Nil 61 0.33 2 72 0.53 0 77 1 83 0 99 1 ND 105 0 108 0 111 0
50 02/01/2001 IDC 14 2 20\39 3+ 3+ Arim 49 0.00 0 ND ND 61 0 65 0 77 1 81 1 84 0 88 1
51 01/01/2000 Multifocal
lobular
carcinoma
17 3 6\18 3+ 3+ Arim 37 0.08 1 51 0.03 0 47 0 51 0 87 0 90 0 93 0 97 0 100 1
Arim¼arimidex; BM¼bone marrow; CT¼chemotherapy; CTCs¼circulating tumour cells; DCIS¼ductal carcinoma in situ; DTCs¼disseminated bone marrow tumour cells; ER¼oestrogen receptor; FEC¼fluorouracil, epirubicin
and cyclophosphamide; ICC¼immunocytochemistry; IDC¼infiltrating ductal carcinoma; ILC¼infiltrating lobular carcinoma; ND¼not done; Neg¼negative; PB¼peripheral blood; Pos¼positive; PR¼progesterone receptor;
QPCR¼quantitative PCR; Tam¼tamoxifen. High-risk patients therapy and monitoring details. Results for CTCs and DTCs in 33 group III high-risk primary breast cancer patients.
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sin a metastatic cascade (Pantel and Brakenhoff, 2004; Pantel et al,
2008).
We have monitored patients with primary breast cancer using
sequential bone marrow aspirates for several years. Although these
results indicate that a proportion of patients have PCR or
immunocytochemical evidence of micrometastases, the test is
confounded by the problem of sampling errors and in disease
variability. In our study (Slade et al, 2005), we followed up 131
primary breast cancer patients for 4 years after surgery with
bone marrow aspirates; 73% showed a fall in the micrometastatic
load as measured by PCR and 63% as determined by ICC during
follow-up. Of 91 patients who had repeat samples assayed, 87 and
65% had positive results at some time using PCR and ICC,
respectively.
Patients are reluctant to have bone marrow tests more often
than every 6 months, and thus it is difficult to even repeat the test
to see whether the result is consistent. The CellSearch system,
requiring only a peripheral blood sample, can be used frequently
during follow-up. Our results indicate that either CTC sampling or
a combination of blood and bone marrow tests may provide a
practical monitoring system for breast cancer patients on follow-
up. In our experience, many patients find repeat bone marrow
sampling difficult and painful; this study suggests that the number
of CTCs found on blood sampling is similar to the number found
in bone marrow samples. Thus, blood tests may, in the future, be
used in place of bone marrow sampling. However, before this can
be recommended, we believe that a prospective study should be
done comparing both tests.
Others have shown that the persistence of DTCs after treatment
indicates a poor prognosis. Braun et al (1999, 2000a) investigated
the effect of 500mg of Edrecolomab on bone marrow micro-
metastases in 10 primary breast cancer patients before and at days
5–7 after antibody treatment. They showed a reduction in the
number of disseminated cells after therapy. We (Smith et al, 2000)
analysed 145 blood samples obtained from 22 metastatic breast
cancer patients, both by immunocytochemistry and PCR, over 13
months. Of the 25 assessable courses of treatment, PCR agreed
with the clinical outcome in 17 cases (68%) and ICC in 12 cases
(48%). When 356 disease-free patients (Wiedswang et al, 2003)
were subsequently analysed with a second bone marrow aspirate
after a 3-year follow-up, the presence of micrometastases at this
stage in disease-free patients was shown to be an independent
prognostic factor (Wiedswang et al, 2004). Stathopoulou et al
(2003) used real-time RT–PCR to study 77 patients with primary
breast cancer before and after adjuvant chemotherapy, and showed
a marked reduction both in the number of positive patients (31.2–
6.5%) and in the level of positivity. They also studied 47 patients
with overt metastases before and after chemotherapy and found no
differences either in the number of patients positive (40.4 and
42.6%) or in the levels of positivity. In a study of 228 patients
followed up with a repeat bone marrow aspirate 21 months after
diagnosis, Janni et al (2005) showed that recurrence-free survival
in patients with no DTCs was 149.7 months compared with 86.5
months in patients positive for DTCs (P¼0.0003) and that overall
survival was 162.1 months compared with 98.7 months
(P¼0.0008), respectively.
Recently, the need for a monitoring system has been highlighted
by several trials indicating that sequential treatment during the
disease-free period may improve overall survival in breast cancer.
Thus, the Inter-Group Exemestane Study (IES) and Arimidex-
Noluadex (ARNO)/Austrian Breast Cancer Study Group (ABCSG)
studies both indicate that this approach may be preferable, as does
the concept of sequencing chemotherapy, such as indicated by the
studies using anthracyclines followed by taxanes. We feel that further
adjuvant therapy during the follow-up period may yield better
results, providing that these patients are selected on the basis of
residual DTCs or CTCs.
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